Argos Therapeutics Inc (ARGS) Shares Down 19% on Analyst Downgrade

Argos Therapeutics Inc (NASDAQ:ARGS) fell 19% on Monday after Stifel Nicolaus lowered their price target on the stock to $1.20. Stifel Nicolaus currently has a hold rating on the stock. Argos Therapeutics traded as low as $1.00 and last traded at $0.81, with a volume of 742,392 shares traded. The stock had previously closed at $1.00.

Several other research firms have also recently weighed in on ARGS. Zacks Investment Research upgraded Argos Therapeutics from a “hold” rating to a “buy” rating and set a $6.00 target price for the company in a research note on Monday, January 16th. FBR & Co restated a “buy” rating and set a $13.00 target price on shares of Argos Therapeutics in a research note on Tuesday, January 17th. Needham & Company LLC restated a “buy” rating and set a $10.00 target price on shares of Argos Therapeutics in a research note on Friday, December 9th. Finally, JMP Securities cut Argos Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 22nd. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $8.03.

A number of large investors have recently modified their holdings of the stock. State Street Corp boosted its stake in shares of Argos Therapeutics by 11.7% in the fourth quarter. State Street Corp now owns 177,494 shares of the biopharmaceutical company’s stock worth $870,000 after buying an additional 18,625 shares in the last quarter. Wasatch Advisors Inc. boosted its stake in shares of Argos Therapeutics by 35.2% in the third quarter. Wasatch Advisors Inc. now owns 3,228,741 shares of the biopharmaceutical company’s stock worth $16,047,000 after buying an additional 840,260 shares in the last quarter. Finally, Sanders Morris Harris Inc. boosted its stake in shares of Argos Therapeutics by 109.9% in the third quarter. Sanders Morris Harris Inc. now owns 241,512 shares of the biopharmaceutical company’s stock worth $1,201,000 after buying an additional 126,475 shares in the last quarter. Institutional investors own 15.25% of the company’s stock.

The firm’s 50 day moving average price is $2.93 and its 200 day moving average price is $4.34. The stock’s market capitalization is $35.06 million.

var userip;Your IP Address: document.write(userip);

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

5 Day Chart for NASDAQ:ARGS

Receive News & Ratings for Argos Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Burberry Misses Estimates on Sales
Burberry Misses Estimates on Sales
Snapchat: CEO Did Not Label India as Being Poor
Snapchat: CEO Did Not Label India as Being Poor
Credit Suisse Slashes Bonuses by 40%
Credit Suisse Slashes Bonuses by 40%
Daily Mail to Pay Melania Trump $3 Million
Daily Mail to Pay Melania Trump $3 Million
New York Approves Free College Tuition
New York Approves Free College Tuition
Obamacare Market in Iowa Hit Hard by Aetna
Obamacare Market in Iowa Hit Hard by Aetna


© 2006-2017 Ticker Report. Google+.